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Computational studiesPalonosetron (Aloxi) is a potent second generation 5-HT3 receptor antagonist whose mechanism of action
is not yet fully understood. Palonosetron acts at the 5-HT3 receptor binding site but recent computational
studies indicated other possible sites of action in the extracellular domain. To test this hypothesis we
mutated a series of residues in the 5-HT3A receptor subunit (Tyr73, Phe130, Ser163, and Asp165) and in
the 5-HT3B receptor subunit (His73, Phe130, Glu170, and Tyr143) that were previously predicted by in silico
docking studies to interact with palonosetron. Homomeric (5-HT3A) and heteromeric (5-HT3AB) recep-
tors were then expressed in HEK293 cells to determine the potency of palonosetron using both fluorimet-
ric and radioligand methods to test function and ligand binding, respectively. The data show that the
substitutions have little or no effect on palonosetron inhibition of 5-HT-evoked responses or binding.
In contrast, substitutions in the orthosteric binding site abolish palonosetron binding. Overall, the data
support a binding site for palonosetron at the classic orthosteric binding pocket between two 5-HT3A
receptor subunits but not at allosteric sites previously identified by in silico modelling and docking.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Cys-loop receptors constitute one of the largest families of li-
gand-gated ion channels responsible for the transmission of fast
synaptic impulses in the CNS and PNS. The nicotinic acetylcholine,
glycine, GABAA and 5-HT3 receptors, all belong to this family, shar-
ing homologous amino acid sequences and similar arrangements of
subunits.1,2 The 5-HT3 receptor is formed by a pentameric assem-
bly of identical (homomeric) or different (heteromeric) subunits
surrounding a central ion-conducting pore. Each subunit has an
extracellular domain, a transmembrane domain and an intracellu-
lar domain. The binding pocket is formed between two adjacent
subunits, and is constituted of the + (or principle) face of one sub-
unit and the  (or complementary) face of the adjacent subunit
(e.g., A+Awhen between two 5-HT3A receptor subunits). To date,five different 5-HT3 receptor subunits have been identified. Recep-
tors that contain only 5-HT3A receptor subunits (5-HT3A recep-
tors) or 5-HT3A and 5-HT3B receptor subunits (5-HT3AB
receptors) have been widely investigated, but receptors containing
5-HT3C, 5-HT3D and 5-HT3E receptor subunits have been less well
characterized.1–8
Radioligand binding and in situ hybridization studies have
shown that 5-HT3 receptors are present throughout the nervous
system, and play a role in a variety of nervous and sensory func-
tions, as well as in emesis, cognition and anxiety.1,3,4 A number
of 5-HT3 receptor antagonists are therapeutic agents, including
ondansetron, tropisetron, granisetron and palonosetron, with ma-
jor uses in the management of chemotherapy-induced, radiation-
induced and post-operative nausea and vomiting.5
Palonosetron is the newest 5-HT3 receptor antagonist licensed
for clinical use and demonstrates improved control of acute
(0–24 h) and delayed (24–120 h) emesis after moderate chemo-
therapy administration when compared to early generation antag-
onists such as granisetron (Kytril). Palonosetron also has a higher
in vitro binding affinity for the 5-HT3 receptor compared to other
antagonists (pKi of 10.5 vs 8–9), and an extended in vivo plasma
elimination half-life.6,7 Palonosetron has unique structural
characteristics when compared to other drugs in its class and data
suggest that palonosetron interacts with 5-HT3 receptors
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cating allosteric effects and positive cooperativity.12,13 These
authors also provided data that suggests palonosetron triggers
receptor internalisation, resulting in a long-lived inhibition of
receptor function, although more recent data show that the disso-
ciation of palonosetron is very slow, which could explain this
effect.8,9
Recent computational work modelled the extracellular domain
of the human 5-HT3A and 5-HT3B subunits assembled into homo-
and heteromeric receptors to yield A+A and B+A interfaces.10
Docking of serotonin, palonosetron and granisetron into these
binding interfaces was used to probe the binding characteristics
of palonosetron (Fig. 1), with the aim of providing a viable explana-
tion for the higher efficacy of palonosetron, as well as investigating
the allosteric binding and positive cooperativity. These studies sug-
gested a second binding site for palonosetron at the A+A interface
that was not found for granisetron; this was located below the
5-HT binding site, closer to the membrane. Palonosetron was also
proposed to bind to a B+A interface. In silico studies such as these
are increasingly being used to probe the mechanism of action of
drugs, but because many of these use homology models, it is essen-
tial such data are confirmed using experimental studies. The pres-
ent work uses HEK293 expressed mutant 5-HT3A and 5-HT3AB
receptors to experimentally probe the residues identified as inter-
acting with palonosetron in the previously published in silico study
(Fig. 2, Table 1).
2. Materials and methods
2.1. Materials
All cell culture reagents were obtained from Gibco BRL (Paisley,
UK), except foetal calf serum which was from Labtech International
(Ringmer, UK). [3H]Granisetron (84.5 Ci/mmol) was from PerkinEl-
mer (Boston, MA). FlexStation membrane potential dye was from
Molecular Devices Ltd (Wokingham, UK). [3H]Palonosetron
(37.2 Ci/mmol) was custom synthesised for Helsinn Healthcare
(Lugano, Switzerland), and both this and the unlabelled form of
palonosetron were kindly gifted by Helsinn Healthcare (Lugano,
Switzerland). All other reagents were of the highest obtainable
grade.
2.2. Cell culture
Human embryonic kidney (HEK) 293 cells were cultured on
90 mm tissue culture plates at 37 C and 7% CO2 in a humidifiedFigure 1. (A) A homology model of the human 5-HT3A receptor showing the 5-HT
binding site (orange square), a potential allosteric binding site (blue square) and the
location of the 5-HT3A subunit residues (stick representation) mutated in this
study; inset: the potential allosteric binding site predicted by homology modelling
and in silico docking, showing the 5-HT3A subunit residues mutated in this study;
(B) homology model of the human 5-HT3B subunit showing the residues mutated in
this study.atmosphere. They were grown in DMEM:F12 (Dulbecco’s Modified
Eagle’s Medium/Nutrient Mix F12 (1:1)) with GlutaMAX I™ con-
taining 10% fetal calf serum and passaged when confluent. For radi-
oligand binding studies, cells in 90 mm dishes were transfected at
60–70% confluency using polyethyleneimine and incubated for 3–
4 days before use. For FlexStation assays, transfected cells were
plated on 96-well plates and incubated 1–2 days before assay.
2.3. Site-directed mutagenesis
Mutagenesis reactions were performed using either the Kunkel
method or the QuikChange kit (Agilent Technologies Inc., CA, USA)
using human 5-HT3A or 5-HT3B receptor subunit cDNA (accession
numbers: P46098 and O95264) in pcDNA3.1 (Invitrogen, Paisley,
UK). Subunit numberings have been altered to the aligning resi-
dues in the mouse 5-HT3A subunit for ease of comparison with
other studies.
2.4. Radioligand binding
Transiently transfected cells were washed twice with 2 ml
phosphate-buffered saline (PBS), harvested into 1 ml cold HEPES
buffer (10 nM, pH 7.4) containing protease inhibitors (1 mM EDTA,
50 lg/ml soybean trypsin inhibitor, 50 lg/ml bacitracin and
0.1 mM phenylmethylsulphonyl fluoride) and frozen at 20 C.
Once thawed, membranes were washed and resuspended in ice-
cold HEPES buffer.
Eight-point binding assays were performed to produce satura-
tion binding curves. Membrane suspensions (50 ll) in 0.5 ml
HEPES buffer were incubated at 4 C with 0.05–2 nM [3H]-granise-
tron (for 1 h) or [3H]-palonosetron (for 24 h). Unlabelled quipazine
(0.1 mM) was used to determine non-specific binding. Membranes
were harvested onto presoaked (0.3% polyethyleneimine) GF/B fil-
ters using a Brandel harvester, followed by two 2 ml washes of ice-
cold HEPES buffer. Radioactive counts were measured using a
Beckman LS6000SC liquid scintillation counter (Fullerton, Califor-
nia, USA).
Data were analyzed by iterative curve fitting using GraphPad





where B is the amount of bound radioligand, Bmax is the maximum
specific binding at equilibrium, [L] is the concentration of radioli-
gand, Kd is the equilibrium dissociation constant of the radioligand,
and n is the Hill coefficient.
2.5. Functional studies
Fluorometric studies were undertaken using a FlexStation
(Molecular Devices, Sunnyvale, CA, USA) as previously described.11
Transfected cells grown on 96-well plates were washed using a
standard buffer (10 mM HEPES, 115 mM NaCl, 1 mM KCl, 1 mM
CaCl2, 1 mM MgCl2, 10 mM glucose, pH 7.4), loaded with FLIPR
Membrane Potential Dye (Molecular Devices) according to the
manufacturer’s instructions, and then incubated at 37 C for
45 min before being assayed.
Fluorescence was measured every 2 s for 200 s. At 20 s, 50 ll of
buffer or 5-HT (final concentration 0.003 lM to 1.0 mM) was
added to each well. For experiments using palonosetron (0.01
nM–3.0 lM) the antagonist was incubated for 45 min with the
cells before starting the experiment using an EC50 concentration
of 5-HT (unless otherwise stated). Concentration–response and
inhibition curves were obtained for each mutant, and the fluores-
cence values were normalized to the maximal response. The data
were fitted using GraphPad Prism v5.0 using the equation:
Table 2
Affinities of mutant 5-HT3A and 5-HT3AB receptors for [3H]-granisetron and
[3H]palonosetron
Mutant Granisetron Palonosetron
Kd (nM) n Kd (nM) n
5-HT3A subunit mutations
WT 5-HT3A 0.53 ± 0.15 5 0.32 ± 0.07 4
Y73A 0.60 ± 0.11 4 0.87 ± 0.04* 3
Y73F 0.90 ± 0.29 4 0.25 ± 0.04 3
Y73S 0.41 ± 0.11 4 0.61± 0.11 5
W90C NB 8 NB 3
F130A 0.78 ± 0.26 3 0.67 ± 0.12 4
F130Y 0.49 ± 0.17 4 0.26 ± 0.09 3
S163A 0.36 ± 0.19 3 0.30 ± 0.08 4
S163T 0.19 ± 0.09 6 0.22 ± 0.05 6
D165A 0.37 ± 0.11 4 0.30 ± 0.08 3
D165 K 0.44 ± 0.09 5 0.36 ± 0.02 4
W183C NB 6 NB 3
5-HT3B subunit mutations
WT 5-HT3AB 0.20 ± 0.03 4 0.18 ± 0.02 4
H73A 0.22 ± 0.02 3 0.14 ± 0.02 3
W90C 0.25 ± 0.10 4 0.34 ± 0.06 6
F130A 0.78 ± 0.01* 3 0.48 ± 0.03* 3
Y143A 0.20 ± 0.02 3 0.18 ± 0.04 3
E170A 0.11 ± 0.02 3 0.21 ± 0.03 3
I183A 0.16 ± 0.05 3 0.23 ± 0.12 3
* Significantly different to WT, p <0.05; NB = no binding.
Table 1
Human 5-HT3R residues mutated in this study and their corresponding residues in mouse
Mutated residue (mouse numbering) Human numbering ECD Loop Predicted docking interaction Mutant
5-HT3A subunit mutations
Y73 Y68 Hydrophobic/aromatic interactions. A F S
W90 W85 D Aromatic box component C
F130 F125 A p–p interaction with the aromatic region A Y
S163 S158 Cys <5 Å A T
D165 D160 Cys Possibility of a charge-reinforced H-bond with the cationic head A K
W183 W178 B Aromatic box component C
5-HT3B subunit mutations
H73 H66 A
W90 W83 B Aromatic box component C
F130 F123 A p–p interaction with the aromatic region A
Y143 Y136 E A
E165 E158 Cys Charge-induced H bond with the primary amine A
I183 I176 B Aromatic box component A
Figure 2. Previous predicted binding mode of palonosetron into the A+A (A), and B+A (B) interfaces, showing the interactions identified these in silico studies.10
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where F is the fluorescence, Fmax is the maximum response, Fmin is
the baseline fluorescence, [L] is the ligand concentration, nH is the
Hill coefficient, and the EC50 is the ligand concentration required
to obtain 50% of maximal fluorescence.
2.6. Statistical analysis
Values are presented as mean ± SEM. Statistical analysis was
performed using ANOVA in conjunction with a Dunnett’s post-
hoc test; p <0.05 was taken as statistically significant.
3. Results
3.1. Probing the novel palonosetron binding site
3.1.1. [3H]Granisetron radioligand binding
3.1.1.1. Wild type receptors. [3H]-granisetron saturation
binding experiments showed similar binding affinity for homo-
and heteromeric receptors, (Kd = 0.53 ± 0.15 nM and 0.20 ± 0.03
nM, respectively) consistent with data previously reported.12,13
3.1.1.2. Mutant homomeric receptors. Mutant receptors
(Y73A, Y73F, Y73S, F130A, F130Y, S163A, S163T, D165A and
D165K) had Kd values were not significantly different to wild type
(Table 2).
3.1.1.3. Mutant heteromeric receptors. Most receptors con-
taining mutations in the 5-HT3B receptor subunit (H73A, Y143A,and E170A) had Kd values that were not significantly different to
wild type. F130A containing heteromers showed a small
(fourfold) increase in Kd compared to wild type receptors
(Table 2).
Table 4
Palonosetron concentration-inhibition parameters of 5-HT3A and 5-HT3AB receptors
Receptor IC50 (nM) n
5-HT3A subunit mutations
WT 5-HT3A 0.83 ± 0.49 5
Y73A 13.1 ± 1.6* 3
Y73F 1.23 ± 0.15 4
Y73S 3.64 ± 1.1 3
W90C NF 3
F130A 4.40 ± 1.8 3
F130Y NF 9
S163A 1.57 ± 0.12 3
S163T 1.02 ± 0.19 3
D165A 1.33 ± 0.45 3
D165 K 1.30 ± 0.43 3
W183C NF 3
5-HT3B subunit mutations
WT 5-HT3AB 0.88 ± 0.15 11
H73A 0.97 ± 0.26 7
W90C 0.37 ± 0.10 4
F130A 0.84 ± 0.11 5
Y143A 0.38 ± 0.05 9
E170A 0.36 ± 0.11 5
I183A 0.34 ± 0.08 4
* Significantly different to WT, p <0.05. NF = non functional. WT = wild type.
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3.1.2.1. Wild type receptors. [3H]Palonosetron bound with
similar high affinity to 5-HT3A and 5-HT3AB receptors (Kd = 0.32
± 0.07 and 0.18 ± 0.07 nM, respectively) (Table 2), a finding consis-
tent with previous studies.6,7
3.1.2.2. Mutant homomeric receptors. Most mutant recep-
tors (Y73F, F130A, F130Y, S163A, S163T, D165A and D165K) had
Kd values similar to wild type. There was a small increase in Kd
(2.5-fold) for Y73A receptors.
3.1.2.3. Mutant heteromeric receptors. Most mutant recep-
tors containing subunits with 5-HT3B subunit mutations (H73A,
W90C, Y143A, and E170A) had Kd values similar to wild type, but
there was a small increase (twofold) in Kd for F130A containing
heteromers.
3.1.3. Functional assays
3.1.3.1. Wild type receptors. Our functional responses of WT
5-HT3AB receptors expressed in HEK cells and studied using mem-
brane potential sensitive dye show a similar EC50 and a decrease in
Hill slope (EC50 = 0.5 lM, nH = 1.3) when compared to wild type
5-HT3A receptors (EC50 = 0.32 lM, nH = 2.3). These data are similar
to previous reports.14–16
3.1.3.2. Mutant homomeric receptors. One of the mutant
receptors, F130Y, was non-functional. As this mutant had binding
characteristics similar to wild type, this indicates that the presence
of Y at this position produces non-functional receptors. Y73A and
Y73S mutant receptors had lower EC50 values than wild type recep-
tors. All other mutant receptors had EC50 values that were not sig-
nificantly different to wild type (Table 3).
Inhibition studies with palonosetron revealed its IC50 was in-
creased (15-fold) at Y73A containing mutant receptors compared
to wild type receptors. No other receptors were different to wild
type receptors (Table 4).
3.1.3.3. Mutant heteromeric receptors. None of the hetero-
meric receptors had 5-HT EC50 values significantly different to wild
type receptors, and none had differences in IC50 values for palo-
nosetron (Tables 3 and 4).Table 3
5-HT concentration-response parameters of 5-HT3A and 5-HT3AB receptors
Receptor EC50 (lM) Hill Coefficient n
5-HT3A subunit mutations
WT 5-HT3A 0.32 ± 0.05 2.3 ± 0.2 8
Y73A 0.088 ± 0.018* 2.1± 0.3 5
Y73F 0.45 ± 0.07 2.3 ± 0.3 5
Y73S 0.074 ± 0.016* 2.0 ± 0.3 3
W90C NF 3
F130A 0.13 ± 0.03 1.5 ± 0.2 4
F130Y NF 12
S163A 0.16 ± 0.03 3.8 ± 0.4 3
S163T 0.094 ± 0.026 2.5 ± 0.3 2
D165A 0.19 ± 0.03 1.8 ± 0.2 3
D165 K 0.19 ± 0.09 3.0 ± 0.3 6
W183C NF 6
5-HT3B subunit mutations
WT 5-HT3AB 0.50 ± 0.1 1.3 ± 0.2 11
H73A 0.64 ± 0.3 1.6 ± 0.2 7
W90C 0.13 ± 0.1 2.0 ± 0.4 4
F130A 2.4 ± 1.4 1.4 ± 0.2 5
Y143A 3.2 ± 1.7 1.3 ± 0.2 9
E170A 2.6 ± 1.7 1.4 ± 0.2 5
I183A 2.3 ± 0.4 1.2 ± 0.2 4
* Significantly different to WT, p <0.05. NF = non functional. WT = wild type.3.2. Probing the orthosteric binding site
To probe the orthosteric binding site we examined [3H]palo-
nosetron binding to receptors that had substitutions at two critical
binding site residues in the 5-HT3A subunit; W183 in loop B, and
W90 in loop D. The binding characteristics of receptors containing
Cys substitutions at these locations revealed no saturable, specific
binding with [3H]palonosetron (Table 2). This is consistent with
previously published data from [3H]granisetron binding studies,
and indicates that palonosetron binds in this pocket. Lack of spe-
cific [3H]palonosetron binding could alternatively indicate that
the mutant receptors were not expressed, but we consider this is
unlikely as a previous work has demonstrated cell surface expres-
sion of 5-HT3 receptors with mutations of W90 and W183.17
To probe possible binding to A+B, A+B, B+A or B+B inter-
faces in 5-HT3AB receptors, we also substituted the equivalent res-
idues in the 5-HT3B subunit (I183 and W90) and co-expressed
them with wild-type 5-HT3A subunits. [3H]palonosetron binding
data revealed that binding affinities and functional responses were
unaltered in these modified 5-HT3AB receptors.4. Discussion
Palonosetron is a potent 5-HT3 receptor antagonist that has im-
proved properties for ameliorating the symptoms of chemother-
apy-induced and post-operative nausea and vomiting when
compared to earlier antagonists. A possible explanation for this
high potency is the presence of an allosteric binding site, and such
a site was suggested in a computational study by Moura Barbosa
et al.10 Here we used mutagenesis to probe the proposed interac-
tions between palonosetron and residues in the second A+A bind-
ing site and those in the 5-HT3B containing binding sites; the data
confirm previous studies that show palonosetron binds to the
orthosteric binding site located between two adjacent 5-HT3A
subunits (with no contribution from 5-HT3B subunits), but do not
support an alternative binding location.6,7,18,13 There was
some indication that Y73 had an interaction with palonosetron,
although the effects of mutating this residue were small. The roles
of each of the residues that we examined are discussed in more
detail below.
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presented by Moura Barbosa et al.,10 shows a side to edge interac-
tion with palonosetron (Fig. 2). Our substitutions here caused a
small increase in the Kd for palonosetron binding and the IC50 for
inhibition of 5-HT-induced responses, suggesting that Y73 does
not have a major interaction with palonosetron, but may influence
the orthosteric site above, or may form part of a temporary binding
location on route to the ‘classic’ binding pocket; a simulation study
showing the trajectory of granisetron as it unbinds from the recep-
tor indicates that ligands exits below the binding site close to
Y73,19 although altering the equivalent residue in mouse 5-HT3
receptors has no effect on [3H]granisetron binding.20 Therefore, it
is more likely that this residue is structurally important, as sug-
gested in a recent computational work, where molecular dynamics
simulations and computational alanine scanning mutagenesis re-
vealed that Y73 is part of the ‘hot centre’ of the subunit–subunit
interaction, an aromatic cluster located in the middle of the bind-
ing interface involved in the stabilization of the protein.21,22 Fur-
ther evidence for a structural role for this residue comes from
our EC50 values, which are lower for Y73A and Y73S mutant
receptors.
F130 is located on loop A and has been extensively investigated
in mouse 5-HT3A receptors, where it has been shown to have an
important role in function: mutation to Ala or Trp decreases the
5-HT EC50 yet increases the granisetron Kd, while mutation to Tyr
increases the EC50 but has no effect on the Kd.23,24 These data sug-
gest that this residue does not directly bind ligand, but that adding
a hydroxyl is deleterious to receptor function; our results from hu-
man 5-HT3 receptors reveal a similar but more pronounced effect
as F130Y-containing receptors are expressed but are non-func-
tional. The equivalent residue in the 5-HT3B subunit was the only
mutated residue (F130A) that caused an increase in granisetron
binding affinity. There is currently no evidence that granisetron
binds to a 5-HT3B subunit-containing binding pocket, and we sug-
gest that this mutation causes a subtle change in receptor structure
that influences the ligand binding (A+A) interface. Support for
this hypothesis comes from our palonosetron binding data, which
reveals a small increase in affinity in receptors containing F130A-
containing 5-HT3B receptor subunits. There was, however, no
change in EC50 suggesting no significant effect on agonist binding
and/or channel gating. There was also no effect on palonosetron
inhibition of function, suggesting the inhibitory effect of palonose-
tron does not involve binding to F130.
S163 is located below the binding pocket and was predicted to
be <5 Å from palonosetron in the allosteric site proposed by Moura
Barbosa et al.,10 but not directly involved in its binding. Our data
showed that mutation of S163 to either Ala or Thr resulted in no
significant changes to binding or functional parameters, suggesting
this residue does not play a significant role in palonosetron binding
or receptor function. This is in agreement with a previous study
that also concluded that there was no involvement of this Ser in
channel activation or in coupling of ligand binding to channel gat-
ing as this residue was found to be a ‘warm spot’ only involved in
subunit–subunit interactions stabilising the receptor.21
D165 lies further from the orthosteric binding pocket than the
residues discussed above but is a potentially novel palonosetron
binding site identified in the Moura Barbosa et al. study,10 and is
also on the unbinding pathway for 5-HT and granisetron.19 How-
ever our data revealed that mutation of D165 to either Ala or Lys
resulted in no significant changes to binding or functional param-
eters, suggesting this residue does not play a role in palonosetron
binding.
The docking study of Moura Barbosa et al.10 was aimed at prob-
ing whether ligands could bind to an A+A or a B+A interface.
These interfaces were chosen because the critical residues that dif-
fer between 5-HT3A and 5-HT3B receptor subunits are on the prin-cipal face, and thus A+A would be equivalent to A+B, and B+A
equivalent to B+B, covering all possible subunit interface combi-
nations that could occur in a 5-HT3AB receptor; furthermore com-
putational studies have examined the role played by the
extracellular moieties of the A and B subunits in the formation of
functional or non functional receptors, which have been analyzed
in terms of the hydrophobic and electrostatic properties of the dif-
ferent subunits and their complementarity.25 At that time the stoi-
chiometry of the receptor had been proposed to be BBABA,25 but
more recent data has shown that functional receptors require an
A+A interface and the heteromeric stoichiometry is 3A2B, with
a likely subunit arrangement of AABAB26,13,27 Our current data
show the 5-HT3B subunit mutations have little or no effect on
receptor binding or function, consistent with palonosetron binding
only to an A+A interface, although there may be some allosteric
effects of 5-HT3B subunit mutations, as we have proposed for
F130. A 5-HT3 antagonist that does interact with both the A+A
and A+B interfaces has recently been identified.28 This compound
(VUF10166) shows modified binding and functional effects when
tested on A+B receptor containing mutant 5-HT3B subunits, indi-
cating an allosteric effect at an A+B interface, although it also
competed for granisetron at the A+A- binding site.
5. Conclusions
In conclusion our data support a binding location for palonose-
tron in the orthosteric (A+A) binding site in both homomeric
5-HT3A and heteromeric 5-HT3AB receptors, but do not provide
evidence for a second binding site for palonosetron at either the
proposed allosteric site at the A+A binding site or at the B+A
interface. The question remains as to whether there is another pal-
onosetron binding site elsewhere in 5-HT3A or 5-HT3AB receptors.
This is potentially possible but recent data suggest that at least
some of the unusual effects of palonosetron can be explained by
its unusual kinetics, and thus we consider that a second binding
site is unlikely.
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